Immunomodulatory Effects of Afatinib and Pembrolizumab in EGFR-Mutant NSCLC with Progression on Prior EGFR-TKI

被引：2

作者：

Riess, J. ^{[1
]}

Kelly, K. ^{[1
]}

Schalper, K. ^{[2
]}

Shimoda, M. ^{[3
]}

Lim, S. ^{[1
]}

Monjazeb, A. ^{[1
]}

Danenberg, K. ^{[4
]}

Moore, E. ^{[1
]}

Beckett, L. ^{[1
]}

Mack, P. ^{[1
]}

Maverakis, E. ^{[3
]}

Gandara, D. ^{[1
]}

机构：

[1] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA USA

[2] Yale Univ, Pathol, New Haven, CT USA

[3] Univ Calif Davis, Sch Med, Dermatol, Sacramento, CA USA

[4] Nanthealth, Liquid Genom, Torrance, CA USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期

关键词：

immune microenvironment; EGFR-mutant NSCLC; Immunotherapy;

D O I：

10.1016/j.jtho.2018.08.724

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.04-09

引用

页码：S528 / S528

页数：1

共 50 条

[31] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
Kyoko Otsuka
Akito Hata
Jumpei Takeshita
Chiyuki Okuda
Reiko Kaji
Katsuhiro Masago
Shiro Fujita
Nobuyuki Katakami
[J]. Cancer Chemotherapy and Pharmacology, 2015, 76 : 835 - 841
[32] Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the Phase Ib TATTON study
Ramalingam, Suresh S.
Saka, Hideo
Ahn, Myung-Ju
Yu, Helena
Horn, Leora
Hida, Toyoaki
Cantarini, Mireille
Verheijen, Remy
Wessen, Jonathan
Oxnard, Geoffrey
Ohe, Yuichiro
[J]. CANCER RESEARCH, 2019, 79 (13)
[33] Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression
White, Maya N.
Piotrowska, Zofia
Stirling, Kevin
Liu, Stephen V.
Banwait, Mandeep K.
Cunanan, Kristen
Sequist, Lecia V.
Wakelee, Heather A.
Hausrath, Daniel
Neal, Joel W.
[J]. CLINICAL LUNG CANCER, 2021, 22 (03) : 201 - 209
[34] The Predictive Factors for Post-Progression Survival after EGFR-TKI Failure in Advanced EGFR-Mutant Lung Cancer Patients
Ebisudani, Toshiki
Nakashima, Kei
Misawa, Masafumi
Tokumoto, Akiko
Nemoto, Masahiro
Tsuzuki, Ryuta
Suzuki, Fumi
Yamawaki, Satoshi
Otsuki, Ayumu
Noma, Satoshi
Aoshima, Masahiro
[J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1208 - S1209
[35] Continuous Vaginal Bleeding Induced By EGFR-TKI in Premenopausal Female Patients With EGFR Mutant NSCLC
Yu, Min
Li, Xiaoyu
Wu, Xueqian
Wang, Weiya
Li, Yanying
Zhang, Yan
Zhang, Shuang
Wang, Yongsheng
[J]. FRONTIERS IN ONCOLOGY, 2022, 12
[36] The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in EGFR-Mutant NSCLC
Wang, Zhi
Zhang, Lingling
Xu, Wenwen
Li, Jie
Liu, Yi
Zeng, Xiaozhu
Zhong, Maoxi
Zhu, Yuxi
[J]. JOURNAL OF INFLAMMATION RESEARCH, 2022, 15 : 649 - 667
[37] Sintilimab ± IBI305 Plus Chemotherapy for Patients With EGFR-Mutant Non-Squamous NSCLC Failed to EGFR-TKI Treatment
Lu, S.
Cheng, Y.
Wu, L.
Fang, J.
Li, B.
Han, L.
Zhang, Y.
Pan, H.
Wang, Z.
Sun, Y.
Ye, F.
Hu, Y.
Yu, W.
Zhou, H.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S649 - S649
[38] A Phase lb Study of the Combination of Afatinib and Ruxolitinib in EGFR Mutant Non-Small Cell Lung Cancer (NSCLC) Progressed on EGFR-TKI
Park, Ji Soo
Kim, Hye Ryun
Hong, Min Hee
Cho, Byoung Chul
[J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1069 - S1070
[39] First-Line Continual EGFR-TKI Plus LAT Demonstrated Survival Benefit in Egfr-Mutant Nsclc Patients with Oligoprogressive Disease
Xu, Q.
Liu, H.
Hang, T.
Ren, S.
Zhou, C.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S592 - S592
[40] EGFR-mutant NSCLC may remodel TME from non-inflamed to inflamed through acquiring resistance to EGFR-TKI treatment
Chen, Qianqian
Xia, Liliang
Wang, Jingze
Zhu, Shuxin
Wang, Jing
Li, Xing
Yu, Yongfeng
Li, Ziming
Wang, Ying
Zhu, Guanshan
Lu, Shun
[J]. LUNG CANCER, 2024, 192

← 1 2 3 4 5 →